![](https://g.foolcdn.com/editorial/images/786982/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg)
Why Y-mAbs Therapeutics Stock Got Mashed on Monday
The company didn't quite meet expectations for either trailing results or full-year guidance. Cancer drug developer Y-mAbs Therapeutics (YMAB -11.24%) didn't exactly kick off the stock trading week on a high note. The company's shares closed …